PJSC Polyus
PJSC Polyus (LSE, MOEX - PLZL) ( Polyus or the Company ) notes the announcement by Polyus Service Limited Liability Company, the Company s wholly-owned subsidiary ( Polyus Service ), regarding the results of tenders pursuant to its previously announced tender offer to acquire for cash up to 317,792 ordinary shares of the Company ( Ordinary Shares ), including Ordinary Shares represented by depositary shares ( DSs , and the Ordinary Shares and DSs, together, the Securities ), from minority shareholders (the Tender Offer ).
Prior to the Expiration Time, a total of 1,884,933 Ordinary Shares, including 1,393,361 Ordinary Shares represented by DSs, were properly tendered and not withdrawn in the Tender Offer, which exceeds the maximum number of Securities for which the Tender Offer was made (the Maximum Number of Securities ), and, accordingly, pro-ration will apply.
About Frontier IP Frontier IP unites science and commerce by identifying strong intellectual property and accelerating its development through a range of commercialisation services. A critical part of the Group s work is involving relevant industry partners at an early stage of development to ensure technology meets real world demands and needs. The Group looks to build and grow a portfolio of equity stakes and licence income by taking an active involvement in spin-out companies, including support for fund raising and collaboration with relevant industry partners at an early stage of development.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.c
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Celyad Oncology Successfully Doses First Patient in Expansion Cohort of the CYAD-101 Phase 1 .
Celyad SADecember 15, 2020 GMT
Preliminary data from the expansion cohort are expected during first half 2021
MONT-SAINT-GUIBERT, Belgium, Dec. 15, 2020 (GLOBE NEWSWIRE) Celyad Oncology SA (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer, today announced the successful dosing of the first patient in the expansion cohort of the Phase 1 alloSHRINK trial for CYAD-101, the Company’s allogeneic T cell receptor (TCR) inhibitory molecule (TIM)-based, non-gene edited CAR T candidate for the treatment of refractory metastatic colorectal cancer (mCRC).
Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons – IT Business Net itbusinessnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from itbusinessnet.com Daily Mail and Mail on Sunday newspapers.
Theradiag Announces Its 2021 Financial Calendar
THERADIAG (Paris:ALTER) (ISIN: FR0004197747, Ticker: ALTER), a company specializing in
in vitro diagnostics of autoimmune diseases and theranostics, today announces its schedule for the publication of financial information for 2021.
Events
About Theradiag
Theradiag is the market leader in biotherapy monitoring. Capitalizing on its expertise in the diagnostics market, the Company has been developing, manufacturing and marketing innovative
in vitro diagnostic (IVD) tests for over 30 years.
Theradiag pioneered theranostics testing (combining therapy with diagnosis), which measures the efficacy of biotherapy in the treatment of chronic inflammatory diseases. Going beyond mere diagnosis, theranostics aims to help clinicians set up customized treatment for each patient. This method favors the individualization of treatment, evaluation of its efficacy and the prevention of drug resistance. In response to this challenge, Theradia